Stress CMR in Pediatric Patients With Suspected Coronary Artery Disease

September 6, 2021 updated by: Nicola Stagnaro, Istituto Giannina Gaslini

Concordance Between Stress CMR and Coronary Angiography in Pediatric Patients With Suspected Coronary Artery Disease

stress cMRI with Dobutamine stress agent (stress cMRI), represent the combination of two orders of exams routinely performed (cMRI and stress diagnostic series of exams) without additional risk for the patient, but with the advantage of non-invasiveness and lack of radiation, and less laborious for the participants

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Surgical revascularization or angioplasty are therapeutic options for coronary lesions even in infants and children. Pharmacological stress induced cMRI could provide crucial information such as coronary arteries origin and proximal pathway, wall motion abnormalities, myocardial perfusion and viability, enabling accurate monitoring of symptomatic and non-pediatric patients. Investigators would build a prospective series of stress cMRI exams in pediatric symptomatic and non-patients, with suspected or previously diagnosed coronary artery disease. Investigators would put the results in comparison with ECG, Exercise test, stress Cardiac Ultrasound and Angiography. At the end of the study, if supported by results, the aim is to replace the current diagnostic procedure (ECG, Exercise test, stress Cardiac Ultrasound and Angiography) which need long hospitalization, expose the patient to radiation dose, is uncomfortable for the patient, and is characterized by a non-negligible risk due to invasive procedure, with a single exam (stress cMRI) which is dose-free, minimal risk related, without hospitalization, and less expensive for National Care System.

Study Type

Interventional

Enrollment (Actual)

15

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Genova, Italy, 16100
        • Istituto Giannina Gaslini

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

8 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Between 8 and 18 years-old patients symptomatic and non, with suspected or previously diagnosed coronary arteries disease

    • Coronary artery re-implantation after arterial switch
    • ALCAPA Syndrome, and other anomalies of origin or pathway
    • replacement of aortica valve with pulmonary autograft (Ross procedure)
    • Kawasaki disease
    • primary dilatative cardiomyopathy
    • coronary atresia
    • familiar Hypercholesterolemia
    • bicuspid aortic valve
    • chest pain
    • exertional dyspnea of suspected coronary artery nature
    • coronary artery fistula

Exclusion Criteria:

  • General contraindication to MRI (non MRI compatible device: vascular clips, foreign bodies, coronary and peripheral artery stents, aortic stent grafts, prosthetic heart valves and annuloplasty rings, cardiac occluder devices, vena cava filters and embolisation coils, haemodynamic monitoring and temporary pacing devices, haemodynamic support devices, permanent cardiac pacemakers and implantable cardioverter-defibrillators, retained transvenous pacemaker and defibrillator leads, cochlear implants, claustrophobia, pregnancy and postpartum),

    • contraindication to contrast agent (renal insufficiency, hypersensitivity to the Dotarem active substance or to any of the excipients:)
    • contraindication to stress agent (hypersensitivity to Dobutamine active substance or to any of the excipients)
    • severe arterial hypertension (>/= 220/120 mmHg)
    • unstable angina pectoris
    • significant aortic stenosis
    • complex cardiac arrhythmias including uncontrolled atrial fibrillation
    • hypertrophic obstructive cardiomyopathy
    • myocarditis, endocerditis
    • pericarditis
    • uncontrolled congestive heart failure
    • previous manifestations of hypersensitivity to dobutamine
    • refuse to join the protocol and relative off-label procedures

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: stress cardiac MRI
  • To optimize the scan protocol and the sequence parameters
  • To investigate the clinical compliance of stress induced cardiac MRI in pediatric patients
  • To test the ability of stress cMRI to visualize coronary arteries morphological irregularities, the corresponding wall motion abnormalities and perfusion - viability features
pharmacological stress testing has evolved as an alternative to physical exercise for the detection of inducible myocardial ischemia

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Multiparameters diagnostic concordance
Time Frame: 24 month
• Agreement of results between stress cMRI and the current practice constituted by Exercise test, Stress Cardiac Ultrasound and Invasive Angiography
24 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Efficacy of stress cMRI
Time Frame: 24 month
Predictive value of stress cMRI to determine the incidence of post-surgical complication of switch repair, and other pathological conditions affecting coronary arteries in natural history, in comparison with tradition test. This will be measured the number coronary segments affected, and consequences on wall motion abnormalities
24 month
Incidence of Treatment-Emergent Adverse Events
Time Frame: 24 month
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
24 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 18, 2018

Primary Completion (Actual)

February 28, 2021

Study Completion (Actual)

March 30, 2021

Study Registration Dates

First Submitted

March 15, 2019

First Submitted That Met QC Criteria

July 13, 2019

First Posted (Actual)

July 17, 2019

Study Record Updates

Last Update Posted (Actual)

September 8, 2021

Last Update Submitted That Met QC Criteria

September 6, 2021

Last Verified

September 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Disease

Clinical Trials on stress cardiac MRI

Subscribe